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Certain aromatic amines carcinogenic for the human urinary bladder, such as 4-aminobiphenyl, undergo hepatic metabolic activation to N-hydroxyl-
amines, which are transported to the bladder. During the transport process, these reactive species come in contact with hemoglobin and react with
this blood protein. The principal hemoglobin adduct formed is a cysteine sulfinamide, and quantitative methods have been developed for the analysis
of sulfinamide adducts at the levels present in ordinary human blood specimens. /N-acetylation is an alternative metabolic fate to N-hydroxylation.
The amount of hemoglobin adduct is decreased to the extent that this pathway is increased relative to N-hydroxylation. Thus, the hemoglobin
adduct is sensitive to dose, cytochrome P450-mediated activation, and N-acetyltransferase-mediated detoxification. In addition, it has been shown
that DNA adduct concentration of 4-aminobiphenyl present in human bladder epithelial cells is significantly associated with hemoglobin adduct levels.
Thus, the hemoglobin adduct of 4-aminobiphenyl, and perhaps several other aromatic amines, is a good dosimeter for the target tissue dose of the
ultimate carcinogenic metabolite of these amines. Several studies have been undertaken in which the hemoglobin adducts of aminobiphenyls in
human blood specimens were determined quantitatively. Information concerning exposure status and acetylator phenotype of the same individuals
was obtained simultaneously. The results of these studies indicate that the hemoglobin adduct of 4-aminobiphenyl is closely associated with three
major risk factors for bladder cancer: cigarette smoking, type of tobacco smoked, and acetylator phenotype. They also support a major etiologic role
for aromatic amines in much of human bladder cancer. - Environ Health Perspect 102(Suppl 6):17-21 (1994)
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Introduction
Human urinary bladder cancer is known to
be induced by 2-naphthylamine (2-NA)
(1), 4-aminobiphenyl (4-ABP) (2), and
benzidine (3). Several other related aro-
matic amines have also been implicated as
human bladder carcinogens, including 4,4'-
methylenedianiline (4), 4,4'-methylene-
bis(2-chloroaniline) (5), o-toluidine (6),
and 4-chloro-o-toluidine (7). Three of
these amines, 4-ABP, 2-NA, and o-toluidine,
are present in cigarette smoke (8). Because
these two amines are potent carcinogens
and because cigarette smoking has been
firmly linked to bladder cancer (9), it has
been hypothesized that the arylamines in
cigarette smoke, especially 4-ABP and 2-NA,
are important, if not predominant, etiologic
agents.
The biochemical mechanisms of bladder
cancer induction by aromatic amines are
complex and not yet fully understood, but
some of the essential elements are known
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(10). One of these is oxidation of the
amines to N-hydroxyarylamines. When
they come in contact with hemoglobin, the
hydroxylamines that are generally only
moderately reactive form adducts in very
high yield. Because the adducts formed are
amenable to analysis at the levels present in
nonsmokers as well as smokers (11), they
have come to be used as biomarkers ofaro-
matic amine exposure and metabolism. In
this article, we will explore the utility and





A mechanistic model for certain aromatic
amine-induced bladder carcinogenesis is
presented in Figures 1 to 3. This model is
oriented about the molecular events
thought to be most relevant for 4-ABP-
and 2-NA-induced tumorigenesis. It may
also depict the events leading to hemoglobin
adducts by a variety of other amines,
regardless ofwhether they are bladder car-
cinogens. Other elements might need to be
introduced to extend it to the process of
carcinogenesis by amines with a benzidine-
like structure, among which would be
arachidonic acid-dependent prostaglandin
H synthase catalyzed co-oxidation (12).
A principal feature ofthis model is that
N-hydroxylation is a predominantly
hepatic reaction, catalyzed by cytochrome
P4501A2, not one that takes place in bladder
epithelial cells. Consequently, transport of
the activated amine to the bladder is required.
Perhaps surprisingly, the N-hydroxyaryl-
amine appears to be exported from the liver
directly (13), which may be partly responsi-
ble for the high hemoglobin adduct yields.
From this model, it is clear that hemo-
globin adducts should accurately reflect the
amount of amine that an individual takes
up from the environment, converts to its
proximate carcinogenic form, and exports
into blood. Hemoglobin adducts of aro-
matic amines can thus be considered bio-
markers that give an approximate measure
ofthe biologically effective dose.
The level ofhemoglobin adduct will be
governed by the extent to which other
hepatic metabolism intervenes in the acti-
vation process. Several other metabolic
processes are possible, including acetylation
to form N-aryl acetamides, N-glucuronida-
tion, sulfation ofthe N-hydroxyarylamines,
and oxidation at carbon centers to yield
phenolic amines. At present it is uncertain
whether carbon-centered oxidation is really
a different reaction than N-oxidation.
More likely, both products are formed
through a common cationic intermediate
that precedes substrate-oxygen bond for-
Environmental Health Perspectives 17SKIPPERAND TANNENBAUM
Figure 1. Hepatic metabolism of aromatic amines.
Only those metabolic pathways which are thought to
be most relevant to hemoglobin adduct formation are
shown. Numerous other pathways are known.
Figure 2. Transport of N-hydroxyarylamines from the
liver to the bladder and hemoglobin adduct formation.
In the case of 4-aminobiphenyl, most of the hydroxyl-
amine istransported in its unconjugated form. Hydrolysis
of the unstable N-glucuronide in the bladder and sub-
sequent resorption of free hydroxylamine contributes
only slightly to the blood exposure and hemoglobin
adduct formation.
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Figure 3. Some of the possible secondary metabolism
of N-hydroxyarylamines in bladder epithelial cells that
might influence DNA adduct formation.
mation so that the ratio of N- to C-hydroxyl-
ation is dependent primarily on the distrib-
ution of electron density in the
intermediate cation (14). It is also P450
enzyme-dependent, but to a lesser degree.
The ratio ofphenolic products to hydroxy-
lamine is thus largely invariant.
In contrast, the other hepatic metabo-
lism is subject to potentially considerable
variability. N-Acetylation. may be under
genetic control (15), so phenotype-depen-
dent differences in amine adduct levels may
be displayed (16). Substantial interindivid-
ual variability in sulfotransferase activity is
known, and some of it may be phenotypi-
cally expressed (17). It is not known,
though, which sulfotransferases catalyze the
sulfation of N-hydroxy-4-ABP or N-
hydroxy-2-NA. Likewise, the formation of
N-glucuronides of these amines is not well
characterized. How much these other reac-
tions will influence the yield of hydroxy-
lamines is a function of the relative rate
constants, amine concentrations, and
inhibitor concentrations.
Substantial secondary metabolism of N-
hydroxyarylamines within bladder epithelial
cells almost certainly occurs also. It is
doubtful that any of this further metabo-
lism has any measurable effect on hemoglo-
bin adducts. However, it may affect the
formation ofDNA adducts, as indicated in
Figure 3. Herein may lie a limitation on
the use of hemoglobin adducts to predict
cancer risk, in addition to other such fun-
damental limitations as the nonassociation
ofprotein adducts with DNA adduct repair.
Exposure Assessment
Numerous studies have been conducted
that indicate that hemoglobin adducts of
aromatic amines can be used to reveal
information concerning exposure to the
amines. These studies have focused on pop-
ulations whose exposure to amines is prin-
cipally the result of exposure to tobacco
smoke. It has been shown repeatedly that,
on average, smokers exhibit higher hemo-
globin adducts of aromatic amines than
nonsmokers (16,18-21). No study has
been conducted that has failed to reach this
conclusion.
Two other studies have also found that
the level of adducts in nonsmokers is posi-
tively associated with their exposure to
environmental tobacco smoke (ETS)
(22, unpublished results). High exposure to
ETS was found to result in a roughly 50%
increase in the average levels of 3- and 4-
ABP over that determined in individuals
with minimal exposure. These results seem
to indicate that there remains some exposure
to aromatic amines that is not associated
with tobacco smoke.
The preceding studies have depended
on the comparison of aggregate measure-
ments, necessitated by the considerable
interindividual variability in the response of
the hemoglobin adduct to dose as well as
uncertainty about the degree ofexposure. It
has also been possible to interpret adduct
values in terms thathave individual relevance.
For example, a person with 4-ABP adducts
at the level of 80 to 100 pg/g hemoglobin
might be either a nonsmoker or smoker.
However, smokers who quit smoking will
experience a marked decline in adducts,
regardless of the level present at the time
when they were smoking (23).
The hemoglobin adduct of 4-ABP has
also proven to be highly characteristic for
individual subjects. In an unpublished
study, we analyzed 4-ABP hemoglobin
adducts in 37 subjects at the beginning and
end ofa 14-week period. The correlation of
the two analyses is very good (r = 0.90),
indicating that there is very little change in
adducts over an extended time period.
Analysis of fetal hemoglobin obtained
from cord blood postpartum has revealed
that fetuses are exposed to N-hydroxy-4-
ABP (20). A significant association was
found between fetal levels and the adduct
level in maternal blood sampled at or near
the time ofbirth. The correlation coefficient
was 0.85 when the entire study sample,
including both smoking and nonsmoking
mothers, was analyzed. When only smoking
mothers and their infants were included,
the correlation coefficient was reduced to
0.71 (n = 14), which was still highlysignifi-
cant (p = 0.002). The mechanism of fetal
exposure to N-hydroxy-4-ABP is still
unclear. Numerous possibilities could be
considered, including maternal activation
followed by transplacental transfer, placental
metabolic activation, and fetal activation.
However, fetal liver does not express much
P4501A2 (24), and placental activity
appears to be associated mostly with lAI
(25,26). Thus, maternal metabolic activa-
tion seems most likely.
If hemoglobin adducts reflect exposure
as the foregoing discussion suggests, then
there should be a quantifiable relationship
between the two. The only independent
measure of exposure to aromatic amines
that we have been able to study is exposure
to cigarette smoke. This can be determined
in several ways, including self-reported
number of cigarettes smoked per day,
serum or urinary cotinine levels, and ambi-
ent air monitoring for nicotine. All have
been examined.
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4-Aminobiphenyl adducts have been
positively and significantly associated with
ambient nicotine, increasing 50 to 70%
through three categories ofexposure (unpub-
lished results). These data confirmed the
role of ETS in producing hemoglobin
adducts in nonsmokers but were insuffi-
cient to characterize a dose-response rela-
tionship.
Similarly, we have investigated the cor-
relation between 4-ABP adducts and mea-
sures of cotinine (21,23,27,28), assuming
that cotinine would be a good surrogate
measure of4-ABP intake. Significant corre-
lations have been found, provided the
study samples included sufficient numbers
of light smokers. Among heavy smokers,
though, there is little association of4-ABP
adducts and cotinine. These results are not
too surprising because, while the ratio of
aromatic amines to nicotine in tobacco
smoke may be fairly constant, the conver-
sion ofnicotine to cotinine in vivo issubject
to considerable interindividual variability.
Self-reported cigarette consumption is
the simplest measure of aromatic amine
exposure and we have investigated the rela-
tionship between consumption and adduct
levels in some detail. A nonlinear response
is always observed when those who smoke
more than about 20 cigarettes per day are
included, with increasing consumption
leading to little if any increase in adducts.
A trivial explanation for the nonlinearity is
that the amine dose is not proportional to
consumption ofcigarettes at high numbers
of cigarettes smoked because of a reduced
degree of inhalation, reduced number of
puffs per cigarette, etc. This explanation
probably is not correct, though. Published
(29) and unpublished data from studies of
ethylene oxide-hemoglobin adduct forma-
tion, which is much less subject to metabolic
effects than aromatic amineadductformation,
indicate no such nonlinearity. Carboxyhemo-
globin, likewise a measure that is indepen-
dent of metabolic effects, displays a linear
increase with cigarette consumption (30).
Thus, it is likely that interindividual differ-
ences in metabolism contribute significantly
to the shape ofthe dose-response curve.
The effect of interindividual variability
can also be observed in the range ofadducts
in persons with similar exposure. Figure 4
summarizes all the data collected in this
laboratory for smokers who reported smok-
ing 15 to 25 cigarettes per day. This range
was chosen so that sufficient numbers of
smokers would be included without also
including those individuals whose smoking
habits were unusual. It may be thought of







Figure 4. Distribution of hemoglobin adducts in per-
sons smoking between 15 and 25 cigarettes per day.
per day. Figure 4 shows that there is a
nearly 20-fold range of response in 4-ABP
adducts to smoking one pack per day of
cigarettes. Some of the possible reasons for
such variability have been discussed earlier.
Aromatic Amines as Etiologic
Agents
The attributable risk of cigarette smoking
for bladder cancer is at least 50% (9).
Thus, the repeated finding ofelevated aro-
matic amine adducts in hemoglobin of
smokers is consistent with the hypothesis
that these compounds play a role in initiating
bladder cancer in the majority of cases.
Molecular epidemiologic studies can test
this hypothesis, supporting it if aromatic
amine hemoglobin adducts are positively
associated with known risk factors and
tending to disprove it ifthey are not.
Smoking black tobacco cigarettes rather
than blonde tobacco cigarettes is a risk fac-
tor for bladder cancer (31-34). Chemical
analysis of smoke from each of the two
types of tobacco has revealed that black
tobacco produces higher amounts of aro-
matic amines (8). Consistent with these
observations, smokers ofblack tobacco cig-
arettes have significantly elevated levels of
aromatic amine hemoglobin adducts. Two
studies have shown elevation of 4-amino-
biphenyl adducts. In one ofthese (16), no
other amines were investigated, but in the
other (19), an additional 14 amine adducts
were determined. Four of these were also
significantly associated with tobacco type.
3-Aminobiphenyl adducts were 11 to 12
times higher in smokers than in nonsmokers,
but they showed no association with
tobacco type.
A third risk factor for bladder cancer
that implicates aromatic amines as
causative agents is N-acetylator phenotype.
As of 1988, 12 case-control studies in
which the subjects were phenotyped had
Table 1. Adducts of 4-aminobiphenyl in human hemo-






been published (15). In 11 of these, the
prevalence of slow acetylators among cases
exceeded the prevalence in the controls.
Summary analysis of the combined studies
revealed a relative slow/rapid acetylator
odds ratio of 1.46.
A similar ratio of 4-ABP adducts has
been observed in slow and rapid acetylators
phenotyped by the recently introduced caf-
feine metabolites method (16). In a group
of 50 nonsmokers, the ratio was 1.6, in 31
smokers ofblond tobacco it was 1.3, and in
16 black tobacco smokers it was 1.5. After
adjustment for type and number of ciga-
rettes smoked, it was found that the adduct
levels were significantly related to this
genetic trait.
Epidemiologic studies have yielded con-
flicting results concerning the relationship
between risk and intensity ofsmoking (9).
Some have shown a steadily increasing risk
with increasing number of cigarettes
smoked per day, while others have shown a
plateau at moderately high smoking levels.
As indicated earlier, we have observed that
4-ABP adducts definitely plateau at about
one pack per day. Thus, in the context ofa
dose-response relationship, one cannot
reach anyclearconclusion as towhether these
adducts are strongly associated with risk.
4-ABP hemoglobin adducts appear to
be elevated in individuals with higher 4-
ABP-DNA adducts in bladder epithelium
as determined by 32P-postlabeling (35). An
adduct that chromatographed to a position
consistent with its being N-(deoxyguano-
sin-8-yl)-4-aminobiphenyl was significantly
correlated with hemoglobin adducts
(p = 0.01) in a group of37 normal individ-
uals composed of both smokers and non-
smokers. The data are presented in Table 1.
One case-control study of 4-ABP
hemoglobin adducts and bladder cancer
has been reported (36). In this study, a
modest increase (58%) in adduct levels in
cases was observed relative to the level in
the controls. The difference was statistically
significant by paired t-test and Kruskal-
Wallis rank analysis, but not by logistic
regression analysis. However, an increase of
this magnitude may be all that should be
expected (37). In contrast, a case-control
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study of lung cancer found no association
oflung cancer diagnosis and 4-ABP-hemo-
globin adducts (21). The results from these
two studies both tend to support the
hypothesis that 4-ABP is a human bladder
carcinogen at the doses resulting from
ambient and cigarette smoke exposure.
Limitations
Hemoglobin adducts of aromatic amines
appear to be good dosimeters for biologi-
cally effective dose delivered to the bladder
lumen. To a very limited extent, it has also
been shown that the dose measured in this
way correlates with target tissue DNA
adduct formation. However, it may be
anticipated that several factors could inter-
vene to limit the quality ofthe correlation.
Some ofthese are alluded to in Figure 3.
It has been shown that about 70% of
the N-hydroxylamine formed from 4-ABP
reaches the bladder in unconjugated form,
while the remaining 30% is in the form of
the N-glucuronide (13). The conjugate,
though, is sensitive to acid-catalyzed
hydrolysis (38), and the rate varies consid-
erably in the pH range 5 to 7. Thus, indi-
vidual urine pH plays a significant role in
determining the actual bladder exposure to
free N-hydroxylamine. It also has been
shown that free N-hydroxylamines are
resorbed into blood through the bladder
epithelium (39). Presumably, the rate of
resorption is comparable to the rate of
uptake by epithelial cells. Thus, the fre-
quency ofbladder voiding can affect expo-
sure, since the longer urine is retained, the
more hydroxylamine can hydrolyze and the
more hydroxylamine can be taken up by
epithelial cells. Neither hydrolysis of glu-
curonide conjugates nor frequency ofbladder
voiding influences hemoglobin adducts in
anysignificant way.
Figure 3 suggests that one or more
phase II conjugation reactions are necessary
to convert the N-hydroxylamine proximate
metabolite to an ultimate carcinogen.
Previously it has been suggested that such
metabolic activation is not necessary
because the lower pH of urine would gen-
erate nitrenium ions through protonation
and loss of H20, but this now seems less
likely. Bladder epithelium is known to have
certain N-acetyl transferase activities (40),
and this could activate N-hydroxylamines
by formation of N-acetoxyamines. Sulfo-
transferase activity has also been detected
in bladder cytosol (41). Whether these
observed activities are indicative ofthe cor-
responding specific activities necessary for
the formation of DNA adducts has not
been determined.
Figure 3 also suggests that there may be
one or more mechanisms for detoxifying
carcinogenic N-hydroxylamines, among
which reduction to arylamines might be
important. While there are no studies that
specifically show such reduction in bladder
tissue, it has long been known that the liver
reduces hydroxylamines very efficiently
(42). The main reason, it appears, that
liver exports hydroxylamines at all is that
they are trapped by hemoglobin more
rapidly than they can be reduced. If the
same reductive enzymes are present in
bladder tissue, then they might be expected
to influence the amount of DNA adducts
that could be formed from a given amount
ofhydroxylamine.
Thus, while the specific mechanisms are
not known yet, it is likely that there are
one or more mechanisms that can modulate
the yield of bladder DNA adducts formed
from N-hydroxylamines. Because these
mechanisms are largely independent of
those that lead to hemoglobin adducts, a
certain amount ofvariance in the association
of DNA adducts with hemoglobin adducts
is to be expected. How much variance
remains to be determined. Only one study
in which the correlation between DNA and
hemoglobin adducts was investigated has
been reported. Despite the potential limita-
tions just described, the two adducts were
found to be significantly associated.
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